FDx Advisors Inc. acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 5,073 shares of the medical research company’s stock, valued at approximately $548,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRL. YorkBridge Wealth Partners LLC boosted its stake in shares of Charles River Laboratories International by 445.5% during the 3rd quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock worth $118,000 after acquiring an additional 891 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Charles River Laboratories International by 12.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after acquiring an additional 202 shares in the last quarter. Riverhead Capital Management LLC boosted its stake in shares of Charles River Laboratories International by 14.7% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after acquiring an additional 247 shares in the last quarter. Cambridge Advisors Inc. bought a new stake in shares of Charles River Laboratories International during the 2nd quarter worth $202,000. Finally, Advisor Partners LLC bought a new stake in shares of Charles River Laboratories International during the 2nd quarter worth $208,000. 97.46% of the stock is owned by institutional investors and hedge funds.

In related news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $0.27, for a total transaction of $270,000.00. Also, insider Davide Molho sold 5,982 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $107.55, for a total transaction of $643,364.10. Following the transaction, the insider now directly owns 22,714 shares in the company, valued at $2,442,890.70. The disclosure for this sale can be found here. Over the last quarter, insiders have purchased 10,500 shares of company stock valued at $2,885 and have sold 1,012,147 shares valued at $1,591,514. 2.20% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: This story was reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.watchlistnews.com/5073-shares-in-charles-river-laboratories-international-inc-crl-acquired-by-fdx-advisors-inc/1713903.html.

Several equities research analysts have recently weighed in on CRL shares. Credit Suisse Group reissued a “neutral” rating and set a $112.00 price objective (up from $95.00) on shares of Charles River Laboratories International in a research note on Monday, October 16th. Zacks Investment Research upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 target price for the company in a report on Tuesday, October 24th. Jefferies Group LLC restated a “buy” rating and issued a $120.00 target price on shares of Charles River Laboratories International in a report on Tuesday, September 12th. ValuEngine lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Finally, Royal Bank Of Canada assumed coverage on Charles River Laboratories International in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $110.00 target price for the company. Seven investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $106.63.

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) opened at $101.39 on Friday. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13. Charles River Laboratories International, Inc. has a 1-year low of $69.51 and a 1-year high of $119.05. The stock has a market capitalization of $4,802.03, a price-to-earnings ratio of 19.92, a P/E/G ratio of 1.62 and a beta of 0.94.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.08. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The business had revenue of $464.23 million during the quarter, compared to analyst estimates of $458.93 million. During the same period last year, the company earned $1.18 earnings per share. Charles River Laboratories International’s quarterly revenue was up 9.0% compared to the same quarter last year. analysts predict that Charles River Laboratories International, Inc. will post 5.13 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.